Published in Graefes Arch Clin Exp Ophthalmol on December 09, 2005
[Surgical treatments for retinal vein occlusion]. Ophthalmologe (2007) 0.79
Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion (an AOS thesis). Trans Am Ophthalmol Soc (2008) 0.76
[Arteriovenous dissection for branch retinal vein occlusion]. Ophthalmologe (2008) 0.75
The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol (1993) 9.69
Retinal blood flow in nonischemic central retinal vein occlusion. Ophthalmology (1998) 2.72
Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology (2004) 2.43
Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol (2004) 2.38
Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol (1986) 1.58
The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology (1998) 1.49
Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol (1982) 1.48
Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina (1999) 1.40
Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group. Am J Ophthalmol (1993) 1.35
Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol (1988) 1.18
Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol (1998) 1.17
Vitrectomy with arteriovenous decompression and internal limiting membrane dissection in branch retinal vein occlusion. Retina (2002) 1.08
[Retinal vein occlusions]. Ophthalmologe (2003) 1.01
A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol (1994) 0.98
Arteriovenous crossing dissection without separation of the retina vessels for treatment of branch retinal vein occlusion. Retina (2003) 0.96
[Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion]. Fortschr Ophthalmol (1988) 0.95
Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy, the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol (2003) 0.95
The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol (2003) 0.92
Arteriovenous adventitial sheathotomy for the treatment of macular edema associated with branch retinal vein occlusion. Am J Ophthalmol (2000) 0.89
Adventitial sheathotomy for decompression of recent onset branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2001) 0.84
Arteriovenous dissection in a living human eye: clinicopathologic correlation. Arch Ophthalmol (2005) 0.82
[Erythrocyte aggregation and retinal vein occlusion. Preliminary data for a randomized study on the efficacy of anti-erythrocyte aggregation (troxerutin) in retinal vein occlusion]. Bull Soc Ophtalmol Fr (1989) 0.82
[Isovolemic hemodilution in patients with retinal branch vein occlusion]. Fortschr Ophthalmol (1985) 0.78
Angiographic findings in arteriovenous dissection (sheathotomy) for decompression of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2005) 0.78
Comparative study of vitrectomy with and without vein decompression for branch retinal vein occlusion: a pilot study. Eur J Ophthalmol (2004) 0.77
[Arteriovenous sheathotomy in venous thrombosis]. Klin Monbl Augenheilkd (2004) 0.76
[Efficiency of surgical treatment for chronic macular edema due to branch retinal vein occlusion]. J Fr Ophtalmol (2003) 0.76
[The efficacy of arteriovenous adventitial sheathotomy for macular edema in branch retinal vein occlusion]. Nippon Ganka Gakkai Zasshi (2004) 0.75
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care (2010) 3.29
Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol (2010) 1.67
Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology (2006) 1.52
Toxic vitreitis outbreak after intravitreal injection. Retina (2010) 1.51
Successful treatment of cystoid macular edema with valdecoxib. J Cataract Refract Surg (2007) 1.50
Light emitting diode microscope illumination for green fluorescent protein or fluorescein isothiocyanate epifluorescence. Biotechniques (2005) 1.29
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol (2007) 1.22
Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol (2010) 1.16
Human infection with marten tapeworm. Emerg Infect Dis (2013) 1.13
First-in-class pan caspase inhibitor developed for the treatment of liver disease. J Med Chem (2005) 1.02
The stalk domain and the glycosylation status of the activating natural killer cell receptor NKp30 are important for ligand binding. J Biol Chem (2012) 0.98
Structural insights into regioselectivity in the enzymatic chlorination of tryptophan. J Mol Biol (2009) 0.98
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges (2011) 0.96
Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol (2009) 0.94
Levels of VEGF but not VEGF(165b) are increased in the vitreous of patients with retinal vein occlusion. Am J Ophthalmol (2011) 0.94
Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res (2007) 0.92
Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol (2004) 0.90
Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema. Retina (2010) 0.89
Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol (2011) 0.88
Retinal vascular occlusions: an interdisciplinary challenge. Dtsch Arztebl Int (2008) 0.87
Annular fundus autofluorescence abnormality in a case of macular dystrophy. Doc Ophthalmol (2007) 0.84
Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke. Bioorg Med Chem Lett (2004) 0.83
Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol (2010) 0.83
[S2k-guideline for therapy of acne]. J Dtsch Dermatol Ges (2010) 0.83
Arteriovenous dissection in a living human eye: clinicopathologic correlation. Arch Ophthalmol (2005) 0.82
Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol (2005) 0.81
A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cells. J Biol Chem (2013) 0.81
Expression of fatty acid binding proteins 3 and 5 genes in rat pancreatic islets and INS-1E cells: regulation by fatty acids and glucose. Islets (2010) 0.81
In vivo imaging of choroidal angiogenesis using fluorescence-labeled cationic liposomes. Mol Vis (2012) 0.81
Syndromic choroideremia: sublocalization of phenotypes associated with Martin-Probst deafness mental retardation syndrome. Invest Ophthalmol Vis Sci (2008) 0.81
Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications. Bioorg Med Chem Lett (2003) 0.80
Human intestinal fatty acid binding protein 2 expression is associated with fat intake and polymorphisms. J Nutr (2010) 0.79
Influence of different CLA isomers on insulin resistance and adipocytokines in pre-diabetic, middle-aged men with PPARγ2 Pro12Ala polymorphism. Genes Nutr (2012) 0.78
Angiographic findings in arteriovenous dissection (sheathotomy) for decompression of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol (2005) 0.78
[S3-guidelines for the treatment of psoriasis vulgaris--methods report]. J Dtsch Dermatol Ges (2011) 0.78
Histopathological findings after retinal endovascular lysis in central retinal vein occlusion. Br J Ophthalmol (2007) 0.78
A2E and lipofuscin distributions in macaque retinal pigment epithelium are similar to human. Photochem Photobiol Sci (2015) 0.77
Cyclooxygenase-2 inhibitors: a new therapeutic option in the treatment of macular edema after cataract surgery. J Cataract Refract Surg (2005) 0.77
Local injection of receptor tyrosine kinase inhibitor MAE 87 reduces retinal neovascularization in mice. Mol Vis (2004) 0.76
Genotypes of JC virus, DNA of cytomegalovirus, and proviral DNA of human immunodeficiency virus in eyes of acquired immunodeficiency syndrome patients. J Neurovirol (2005) 0.76
Histopathological findings after retinal endovascular lysis in central retinal vein occlusion. BMJ Case Rep (2009) 0.75
Structure-activity relationships within a series of caspase inhibitors. Part 2: Heterocyclic warheads. Bioorg Med Chem Lett (2005) 0.75
Cells of the vitreous body in Behçet's disease. A case report. Adv Exp Med Biol (2003) 0.75
[Laudatio to the 65th birthday of Heinrich Witschel]. Klin Monbl Augenheilkd (2002) 0.75